Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was downgraded by Zacks.com  from a “get” ranking to a “hold” rating in a research note provided to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on finding and also developing little particle medicine candidates to deal with cancer. The Business‘s products under different stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts additionally just recently talked about the business. Noble Financial editioned a “buy” ranking as well as released a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and established a “purchase” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving average cost of $2.90 and also a two-hundred day moving ordinary cost of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) incomes per share for the quarter, covering analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as an unfavorable net margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, compared to the consensus price quote of $0.06 million. During the very same quarter in the prior year, the company published ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A variety of hedge funds have actually recently bought and sold shares of ONTX. GSA Funding Partners LLP purchased a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Management LP purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and other institutional capitalists own 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the recognition and also growth of oncology therapeutics. It concentrates on finding and also developing small molecule medication candidates to treat cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a free copy of the Zacks research report on Onconova Therapeutics (ONTX).

To learn more concerning research offerings from Zacks Investment Research, visit Zacks.com.

This instantaneous information alert was generated by narrative science modern technology and monetary data from Market in order to supply viewers with the fastest and most exact coverage. This tale was evaluated by Market’s editorial group prior to magazine. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS NOW?

Before you consider Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s top-rated and ideal doing research analysts and also the stocks they recommend to their clients on a daily basis. Market has identified the five stocks that top experts are silently murmuring to their customers to purchase now prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics currently has a “Buy” score amongst experts, premier analysts think these 5 stocks are better acquires.